Verve Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Verve Therapeutics
VERV Stock  USD 5.77  0.55  8.70%   
Verve Therapeutics financial statements provide useful quarterly and yearly information to potential Verve Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Verve Therapeutics financial statements helps investors assess Verve Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Verve Therapeutics' valuation are summarized below:
Gross Profit
9.5 M
Market Capitalization
561.2 M
Enterprise Value Revenue
3.2923
Revenue
32.3 M
Earnings Share
(2.35)
There are over one hundred nineteen available fundamental trend indicators for Verve Therapeutics, which can be analyzed over time and compared to other ratios. All traders should should double-check Verve Therapeutics' current fundamental trends against the trends from 2010 to 2025 to make sure the company is sustainable. Market Cap is likely to drop to about 451.3 M in 2025. Enterprise Value is likely to drop to about 353.8 M in 2025

Verve Therapeutics Total Revenue

33.95 Million

Check Verve Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Verve Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 30.2 M, Interest Income of 8.3 M or Depreciation And Amortization of 3.3 M, as well as many indicators such as Price To Sales Ratio of 13.96, Dividend Yield of 0.0 or PTB Ratio of 1.01. Verve financial statements analysis is a perfect complement when working with Verve Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Verve Therapeutics Correlation against competitors.
For more information on how to buy Verve Stock please use our How to Invest in Verve Therapeutics guide.

Verve Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets470 M647.4 M201.8 M
Slightly volatile
Short and Long Term Debt Total71.3 M70 M48.5 M
Slightly volatile
Other Current Liabilities13.4 M24.3 M6 M
Slightly volatile
Total Current Liabilities27.1 M42.9 M12.9 M
Slightly volatile
Other Liabilities28 M26.7 M8.8 M
Slightly volatile
Property Plant And Equipment Net60.6 M96.7 M25.8 M
Slightly volatile
Accounts Payable4.2 M4.5 M3.1 M
Slightly volatile
Cash104.6 M172.6 M43.9 M
Slightly volatile
Non Current Assets Total65.9 M104.6 M28 M
Slightly volatile
Non Currrent Assets Other8.3 M7.9 M1.8 M
Slightly volatile
Other Assets3.9 M6.2 M2 M
Slightly volatile
Cash And Short Term Investments395 M524.3 M169.9 M
Slightly volatile
Common Stock Total Equity74.9 K71.3 K21.4 K
Slightly volatile
Common Stock Shares Outstanding63.8 M84.6 M52.8 M
Slightly volatile
Short Term Investments290.4 M351.7 M126 M
Slightly volatile
Liabilities And Stockholders Equity470 M647.4 M201.8 M
Slightly volatile
Non Current Liabilities Total91.3 M111.1 M58 M
Slightly volatile
Other Current Assets8.5 M15.2 M3.6 M
Slightly volatile
Total Liabilities118.4 M154 M70.9 M
Slightly volatile
Property Plant And Equipment Gross66.2 M113.8 M28 M
Slightly volatile
Total Current Assets404.1 M542.8 M173.7 M
Slightly volatile
Capital Stock52.6 K89 K22.4 K
Slightly volatile
Non Current Liabilities Other1.2 M1.3 M7.4 M
Pretty Stable
Net Working Capital377 M499.8 M160.8 M
Slightly volatile
Short Term Debt8.9 M10.4 M3.6 M
Slightly volatile
Common Stock52.6 K89 K22.4 K
Slightly volatile
Property Plant Equipment22.7 M21.6 M7.3 M
Slightly volatile
Net Receivables3.5 M3.3 M2.9 M
Slightly volatile
Capital Surpluse792.1 M1 B634.2 M
Slightly volatile
Inventory0.80.90.9813
Slightly volatile
Deferred Long Term Liabilities16 M18 M19.6 M
Slightly volatile

Verve Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income30.2 M28.8 M5.6 M
Slightly volatile
Interest Income8.3 M7.9 M2.1 M
Slightly volatile
Depreciation And Amortization3.3 M6.3 M1.6 M
Slightly volatile
Selling General Administrative31.3 M56.6 M14 M
Slightly volatile
Other Operating Expenses147.6 M261 M67.2 M
Slightly volatile
Research Development116.3 M204.3 M53.2 M
Slightly volatile
Cost Of Revenue3.7 M6.3 M1.7 M
Slightly volatile
Total Operating Expenses147.6 M261 M67.2 M
Slightly volatile
Reconciled Depreciation7.1 M6.8 M1.6 M
Slightly volatile
Selling And Marketing Expenses4.4 M4.9 M5.4 M
Slightly volatile

Verve Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation45.4 M43.3 M9.9 M
Slightly volatile
Begin Period Cash Flow221.5 M211 M43.1 M
Slightly volatile
Other Cashflows From Financing Activities2.3 M2.5 M12.1 M
Pretty Stable
Depreciation7.1 M6.8 M1.6 M
Slightly volatile
Capital Expenditures6.6 M3.7 M3.7 M
Slightly volatile
Issuance Of Capital Stock44.4 M46.7 M71.4 M
Slightly volatile
Total Cash From Financing Activities46.7 M49.2 M80.4 M
Slightly volatile
End Period Cash Flow108.3 M177.3 M45.5 M
Slightly volatile
Change To Netincome27.1 M25.8 M12.6 M
Slightly volatile
Sale Purchase Of Stock37 M38.9 M293 M
Slightly volatile
Cash And Cash Equivalents Changes44.3 M45.6 M57 M
Slightly volatile
Change To Inventory809.6 K910.8 K993 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.9614.6925444
Slightly volatile
Days Sales Outstanding34.9136.7461171
Slightly volatile
Stock Based Compensation To Revenue1.271.33789.7585
Slightly volatile
Capex To Depreciation1.861.9611.928
Slightly volatile
EV To Sales10.9411.5199429
Slightly volatile
Days Of Inventory On Hand0.00.01.0E-4
Slightly volatile
Payables Turnover0.90.952.7029
Pretty Stable
Sales General And Administrative To Revenue1.661.75216.1899
Slightly volatile
Average Inventory0.40.450.4906
Slightly volatile
Research And Ddevelopement To Revenue6.06.320356.2107
Slightly volatile
Capex To Revenue0.110.11565.6023
Slightly volatile
Cash Per Share4.746.22472.7361
Slightly volatile
Days Payables Outstanding4855115.3 K
Slightly volatile
Income Quality0.550.79360.509
Slightly volatile
Current Ratio10.4112.64898.5471
Slightly volatile
Receivables Turnover10.439.9332.9557
Slightly volatile
Capex Per Share0.0880.04440.0667
Slightly volatile
Revenue Per Share0.40.38390.0896
Slightly volatile
Interest Debt Per Share1.260.83090.9175
Slightly volatile
Debt To Assets0.10.10811.1388
Slightly volatile
Operating Cycle34.9136.7461171
Slightly volatile
Days Of Payables Outstanding4855115.3 K
Slightly volatile
Ebt Per Ebit1.220.86751.2865
Slightly volatile
Long Term Debt To Capitalization0.120.10771.5764
Slightly volatile
Total Debt To Capitalization0.120.12421.5719
Slightly volatile
Quick Ratio10.4112.64898.5471
Slightly volatile
Net Income Per E B T0.81.00180.9776
Slightly volatile
Cash Ratio2.384.02151.7385
Slightly volatile
Days Of Inventory Outstanding0.00.01.0E-4
Slightly volatile
Days Of Sales Outstanding34.9136.7461171
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.02371.1908
Slightly volatile
Fixed Asset Turnover0.350.33430.0638
Slightly volatile
Debt Ratio0.10.10811.1388
Slightly volatile
Price Sales Ratio13.9614.6925444
Slightly volatile
Asset Turnover0.05240.04990.0097
Slightly volatile

Verve Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap451.3 M475 M1.3 B
Slightly volatile
Enterprise Value353.8 M372.5 M1.3 B
Slightly volatile

Verve Fundamental Market Drivers

Cash And Short Term Investments524.3 M

Verve Upcoming Events

7th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Verve Therapeutics Financial Statements

Verve Therapeutics investors use historical fundamental indicators, such as Verve Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Verve Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.6 M3.4 M
Total Revenue32.3 M33.9 M
Cost Of Revenue6.3 M3.7 M
Stock Based Compensation To Revenue 1.34  1.27 
Sales General And Administrative To Revenue 1.75  1.66 
Research And Ddevelopement To Revenue 6.32  6.00 
Capex To Revenue 0.12  0.11 
Revenue Per Share 0.38  0.40 
Ebit Per Revenue(7.07)(7.43)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Verve Stock Analysis

When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY